GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Short Interest

Cytokinetics (FRA:KK3A) Short Interest


View and export this data going back to 2004. Start your Free Trial

What is Cytokinetics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Cytokinetics's Short Interest

For the Biotechnology subindustry, Cytokinetics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cytokinetics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cytokinetics's Short Interest distribution charts can be found below:

* The bar in red indicates where Cytokinetics's Short Interest falls into.


Cytokinetics (FRA:KK3A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cytokinetics Inc (FRA:KK3A) » Definitions » Short Interest
Comparable Companies
APLS BBIO MDGL CRSP IONS KRYS HALO IBRX ALPN NUVL OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
CYTK:USA
Address
350 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Website
https://www.cytokinetics.com
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Cytokinetics (FRA:KK3A) Headlines

No Headlines